[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospital of Fudan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":631},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,81,0,25,[9,44,73,103,136,161,186,211,235,262,286,315,337,357,383,402,421,443,467,492,514,545,569,587,607],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100651835","phase-3-zuberitamab-in-the-first-episode-of-paediatric-nephrotic-syndrome-100651835",false,"NCT07765914","Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome","Efficacy and Safety of Single-dose Zuberitamab in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Newly diagnosed steroid-sensitive nephrotic syndrome (SSNS) according to the 2023 IPNA criteria, who achieved complete remission after steroid induction therapy prior to study entry, defined as UPCR (based on first morning void or 24 h urine sample) \\\u003C= 20 mg\u002Fmmol (0.2 mg\u002Fmg), or negative or trace dipstick on three or more consecutive days.\n* An estimated glomerular filtration rate \\>= 90 mL\u002Fmin\u002F 1.73 m2 at study entry.\n* Peripheral blood CD20+ (detected as CD19+) cells \\>= 1% of total lymphocytes.\n* No use of other immunosuppressants within 3 months prior to study entry, other than steroids for nephrotic syndrome.\n\nExclusion Criteria:\n\n* Known etiology including congenital nephrotic syndrome, IgA nephropathy, Henoch-Schönlein purpura nephritis, lupus nephritis, or other secondary nephrotic syndromes.\n* Patients exhibiting any of the following abnormal clinical laboratory values: leukopenia (white blood cells \\\u003C= 3.0 × 10\\^9\u002FL), absolute neutrophil count \\\u003C 1.5 × 10\\^9\u002FL; moderate to severe anemia (hemoglobin \\\u003C 9.0 g\u002FdL); thrombocytopenia (platelet count \\\u003C 100 × 10\\^12\u002FL); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2.5 times the upper limit of normal; positive for any autoimmune markers (ANA, ENA, ANCA, etc.) or decreased complement C3 levels.\n* Evidence of the following infections: severe or opportunistic infection within the previous 6 months (active tuberculosis or history of tuberculosis or suspected tuberculosis; chronic active infections such as EBV, CMV; active hepatitis B presentation or history, or hepatitis C or hepatitis B virus carrier; HIV infection; or other active viral infections).\n* Receipt of live vaccine within one month prior to study entry.\n* History of previous use of biological agents.\n* Current examination suggestive of heart failure, severe arrhythmia, angina pectoris (CTCAE Grade 4), or uncontrolled blood pressure.\n* Severe diseases of vital organs such as the brain or liver, or suffering from hematological or endocrine system disorders.\n* Diagnosis of co-existing autoimmune diseases, primary immunodeficiency, or malignancy.\n* History of organ transplantation (excluding cornea and hair transplants).\n* Known allergy to methylprednisolone, Zuberitamab injection active ingredients or any excipients, sulfamethoxazole (or a contraindication to this drug due to G6PD deficiency).\n* Investigator's judgment that the patient is unsuitable for participation in this study (e.g., patient is highly likely to be lost to follow-up or provide false results, such as alcohol dependence or psychiatric illness).","ALL","1 Year","18 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The goal of this clinical trial is to learn whether adding Zuberitamab to standard corticosteroid therapy can help prevent relapse in children and adolescents aged 1 to 18 years with newly diagnosed steroid-sensitive nephrotic syndrome (SSNS). It will also learn about the safety of Zuberitamab.\n\nThe main questions it aims to answer are:\n\n* Does Zuberitamab plus standard corticosteroid therapy prolong the time to first relapse compared with standard corticosteroid therapy alone?\n* What medical problems do participants experience during treatment?\n\nResearchers will compare Zuberitamab plus standard corticosteroid therapy to standard corticosteroid therapy alone to see whether adding Zuberitamab improves disease control.\n\nParticipants will:\n\n* Receive standard corticosteroid treatment for approximately 12 weeks, with or without a single intravenous infusion of Zuberitamab after achieving remission\n* Take preventive antibiotics if they are in the Zuberitamab group\n* Test their urine daily at home using dipsticks and record results in a diary\n* Visit the clinic for regular checkups and blood and urine tests during follow-up for up to 12 months",[28],"Nephrotic Syndrome",[30],"Anti-CD20 Monoclonal Antibody, Randomised Controlled Trial","NOT_YET_RECRUITING","2026-08-11",{"date":34,"type":35},"2026-08-14","ACTUAL",{"date":37,"type":22},"2026-08-20",{"date":39,"type":22},"2028-12-31",{"name":41,"class":42},"Children's Hospital of Fudan University","OTHER",9,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100646614","phase-2-efficacy-and-safety-of-immunoglobulin-plus-firsekibart-in-patients-with-kawasaki-disease-100646614","NCT07686770","Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease","Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease: An Exploratory Randomized Controlled Study","Inclusion Criteria:\n\n1. Meeting diagnostic criteria for Kawasaki disease (KD) released by American Heart Association (AHA) in 2024\n2. Diagnosed before the tenth day of illness (with the first day of illness defined as the first day of fever)\n3. Not treated with IVIG yet\n4. Age \\>28 days，\\\u003C18 years\n\nExclusion Criteria:\n\n1. Receiving steroids or other immunosuppressive agents in the previous 30 days;\n2. With a previous history of KD;\n3. Afebrile before enrolment;\n4. Contraindications for subcutaneous injection, including severe local skin infection, ulceration, etc;\n5. Known hypersensitivity to immunoglobulins, Firsekibart, or any of the excipients;\n6. With suspected infectious diseases including sepsis, septic meningitis, peritonitis, bacterial pneumonia, varicella and influenza, etc;\n7. With serious immune diseases, such as immunodeficiency, or chromosomal abnormalities;\n8. With severe hepatic dysfunction (ALT \\> 3 times the upper limit of normal) prior to treatment\n9. Unwillingness to provide written informed consent;\n10. Unlikely to complete at least 3 months of follow-up;\n11. Any other conditions deemed unsuitable for enrolment by investigators.","29 Days","17 Years",{"count":54,"type":22},90,[56,25],"PHASE2","This study evaluates the efficacy and safety of the addition of Firsekibart to standard initial treatment (intravenous immunoglobulin \\[IVIG\\] plus aspirin) in children with Acute Kawasaki Disease (KD) .",[59],"Kawasaki Disease",[59,61,62,63],"Firsekibart","Coronary Artery Lesion","IVIG-resistant","2026-07-24",{"date":66,"type":35},"2026-07-27",{"date":68,"type":22},"2026-08-01",{"date":70,"type":22},"2028-02-01",{"name":41,"class":42},2,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100647283","parent-mediated-social-cognition-intervention-for-young-children-with-autism-spectrum-disorder-100647283","NCT07708246","Parent-Mediated Social Cognition Intervention for Young Children With Autism Spectrum Disorder","Efficacy of a Parent-Mediated, Home-Based Structured Play Intervention on Social Cognitive Development in Young Children With Autism Spectrum Disorder: A Non-Randomized Controlled Study","PMSC-ASD","Inclusion Criteria:\n\nChildren：\n\n* Aged 2.5 to 14 years at time of enrollment, with a primary recruitment focus on children aged 3 to 10 years.\n* Meets diagnostic criteria for autism spectrum disorder (ASD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by a specialist clinician.\n* Full-scale intelligence quotient (FSIQ) ≥ 70 as assessed by an age-appropriate Wechsler intelligence scale administered.\n* Possesses sufficient verbal ability to engage with structured play-based intervention activities, as judged by the recruiting clinician.\n* Resides with and is cared for by a participating parent or legal guardian who meets the caregiver eligibility criteria below.\n\nCaregiver：\n\n* Is the primary caregiver (parent or legal guardian) of the enrolled child and resides in the same household.\n* Is able and willing to attend an in-person parent training session (approximately 2.5 hours) at the study site prior to intervention commencement.\n* Is able and willing to commit to administering the structured intervention program to the child for a minimum of 30 minutes per day throughout the 6-month intervention period.\n* Is able and willing to participate in monthly online video supervision sessions with the study clinician.\n* Has sufficient literacy and comprehension ability to understand program training materials and follow intervention procedures.\n* Provides written informed consent on behalf of the child and for their own participation prior to any study procedures.\n\nExclusion Criteria:\n\nChildren：\n\n* Known diagnosis of a genetic syndrome associated with ASD or intellectual disability, including but not limited to Fragile X syndrome, Down syndrome, tuberous sclerosis complex, or Rett syndrome.\n* Presence of a neurological disorder, including epilepsy (unless fully controlled with stable medication for ≥ 12 months), acquired brain injury, cerebral palsy, or other significant neurological condition that may confound assessment of social cognition.\n* Uncorrected vision or hearing impairment that would preclude participation in behavioral or eye-tracking assessments.\n* Currently enrolled in another interventional clinical study targeting social cognition, communication, or behavioral outcomes.\n* Any medical, psychiatric, or developmental condition that, in the opinion of the recruiting clinician, would interfere with the child's ability to participate in or benefit from the intervention.\n\nCaregiver：\n\n* Unable to attend the in-person parent training session at the study site due to geographic, occupational, or other constraints.\n* Unable to commit to the daily home-based intervention schedule or monthly online supervision sessions for the full 6-month intervention period.\n* Presence of significant mental health difficulties or other circumstances that, in the opinion of the recruiting clinician, would substantially impair the caregiver's ability to deliver the intervention with adequate fidelity.","4 Years","8 Years",{"count":84,"type":22},60,[86],"NA","This study evaluates the efficacy of the Companion Mind-Drawing Cooperative Game Program, a parent-mediated, home-based structured play intervention targeting social cognitive development in young children with autism spectrum disorder (ASD).\n\nChildren with ASD in the intervention group will receive a structured program in which parents attend an in-person training session (approximately 2.5 hours) at the hospital, where parents are taught to administer a series of researcher-designed cooperative game paradigms at home. Parents then deliver the intervention daily for at least 30 minutes per session over a period of six months. Monthly online video reviews by a clinician provide parents with individualized feedback and guidance to ensure program fidelity and quality.\n\nChildren with ASD in the comparison group will continue to receive usual care and will not receive the program during the study period.\n\nSocial cognitive outcomes - including emotion recognition, theory of mind, empathy, joint attention, self-perception, and social communication - will be assessed at baseline and at 12-month follow-up using behavioral experimental tasks and eye-tracking paradigms. This study aims to provide evidence for the efficacy of a scalable, family-implemented social cognition intervention for young children with ASD.",[89,90,91,92],"Autism","Intervention (Training) Condition","Social Cognition","Cognition Improvement","RECRUITING","2026-07-13",{"date":96,"type":35},"2026-07-16",{"date":98,"type":35},"2025-06-01",{"date":100,"type":22},"2028-12-30",{"name":41,"class":42},1,{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":102},"100634385","optimizing-early-nutrition-management-of-extremely-andor-very-preterm-infants-100634385","NCT07538999","Optimizing Early Nutrition Management of Extremely and\u002For Very Preterm Infants","Optimizing Early Nutrition Management of Extremely and\u002For Very Preterm Infants Based on Best Clinical Practice: a Real Word Study","Inclusion Criteria for intervention group:\n\n* (1) Admitted to the Neonatal Department of Children's Hospital of Fudan University during the study period.\n* (2) Preterm infants with a gestational age \\\u003C 32 weeks or a birth weight \\\u003C 1500 g.\n* (3) Admitted to the study center within 24 hours after birth.\n* (4) Obtained informed consent from family members. Exclusion Criteria for intervention group\n* (1) Newborns with severe congenital diseases, severe congenital malformations, chromosomal abnormalities, or genetic metabolic diseases.\n* (2) Death or discharge within two weeks after birth.\n\nInclusion Criteria for control group:\n\n* (1) Admitted to the Neonatal Department of Children's Hospital of Fudan University from January 2025 to December 2025.\n* (2) Preterm infants with a gestational age \\\u003C 32 weeks or a birth weight \\\u003C 1500 g.\n* (3) Admitted to the study center within 24 hours after birth. Exclusion Criteria for control group\n* (1) Newborns with severe congenital diseases, severe congenital malformations, chromosomal abnormalities, or genetic metabolic diseases.\n* (2) Death or discharge within two weeks after birth.","1 Day",{"count":112,"type":22},200,[86],"A clinical quality improvement bundle on early nutrition supplementation is developed to improving the clinical outcomes (including growth, organ function, and neurodevelopment outcomes) of extremely and\u002For very preterm infants. This bundle consists of three aspects: individualized and precise human milk feeding, early enteral zinc supplementation, and routine parenteral carnitine supplementation.",[116,117,118],"Nutrition Intervention","Quality Improvement","Preterm Infant",[120,121,122,123,124,125,126,127],"preterm infants","nutrition","bundle","zinc supplementation","carnitine supplementation","growth","outcomes","human milk feeding","2026-07-02",{"date":130,"type":35},"2026-07-06",{"date":132,"type":35},"2026-04-01",{"date":134,"type":22},"2029-12-31",{"name":41,"class":42},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":102},"100617488","application-of-child-life-services-in-pediatric-skin-prick-test-100617488","NCT07319273","Application of Child Life Services in Pediatric Skin Prick Test","Inclusion Criteria:\n\n* Meet the indications for skin prick test (SPT)\n* Aged 1-18 years\n* Voluntarily agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Meet the contraindications for SPT\n* Presence of psychiatric disorders or cognitive impairment\n* Severe dysfunction of vital organs such as the heart, brain, or kidneys",{"count":143,"type":22},140,[86],"The goal of this clinical trial is to determine whether child life services can enhance the experiences of children and caregivers during skin prick testing. The main questions it aims to answer are:\n\n1. Can child life services alleviate children's pain and enhance procedural compliance?\n2. Can child life services reduce caregivers' anxiety and improve their satisfaction? Researchers will compare children who receive child life services with those who receive standard care to determine whether the intervention can optimize procedural experience and overall satisfaction.\n\nParticipants will receive either child life services or standard care during the skin prick test.",[147,148],"Hypersensitivity","Pediatrics",[150,151,152,153,154],"child life services","skin prick test","pain","anxiety","pediatric nursing",{"date":130,"type":35},{"date":157,"type":35},"2026-03-01",{"date":159,"type":22},"2027-06",{"name":41,"class":42},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":17,"minAge":168,"maxAge":19,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":102},"100584500","phase-3-the-efficacy-and-safety-of-dapagliflozin-in-the-treatment-of-hereditary-kidney-disease-with-proteinuria-in-children-100584500","NCT06890143","The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children","The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial","Inclusion Criteria:\n\n* Confirmed diagnosis of hereditary kidney disease (identification of pathogenic genes through molecular genetic testing; for Alport syndrome, molecular diagnosis is not necessarily required if diagnosed based on clinical and pathological findings; for those with a clear family history and a high clinical suspicion of hereditary kidney disease).\n* 24 - hour urinary protein level \\> 0.2 g or urinary protein to creatinine ratio (UPCR) \\> 0.2 mg\u002Fmg.\n* Calculate the estimated glomerular filtration rate (eGFR) using the Schwartz formula (36.5 \\* height in cm \u002F serum creatinine in μmol\u002FL), with eGFR ≥ 60 ml\u002Fmin\u002F1.73 m².\n* Stable use of the basic treatment drug RAASi (including ACEI\u002FARB) for more than 4 weeks, and no dosage adjustment during the treatment period.\n* Willingness to sign the informed consent form.\n\nExclusion Criteria:Exclusion applies if any of the following criteria are met:\n\n* Treatment with hormones\u002Fimmunosuppressive agents within the previous 4 weeks.\n* Treatment with SGLT2 inhibitors within the previous 4 weeks.\n* Comorbid diabetes.\n* Uncontrolled urinary tract infection.\n* Evidence of urinary tract obstruction such as dysuria.\n* Blood pressure below the 5th percentile for the same gender, age, and height.\n* Organ transplantation.\n* Tumor.\n* Presence of any of the following definite evidence of liver disease: ALT\u002FAST reaching 2 times the normal value, hepatic encephalopathy, esophageal varices, or portal shunt surgery.\n* Comorbid medical conditions that may affect drug absorption, distribution, metabolism, and excretion, including but not limited to any of the following: active inflammatory bowel disease within the past 6 months, history of major gastrointestinal surgery (such as gastrectomy, gastroenterostomy, intestinal resection), gastrointestinal ulcer, gastrointestinal or rectal bleeding within the past 6 months, pancreatic injury or pancreatitis within the past 6 months.\n* Subjects at risk of dehydration or volume depletion, which may affect drug efficacy or safety.\n* Participation in other drug trials within the previous 4 weeks.\n* Blood loss exceeding 400 ml within the previous 8 weeks.\n* Poor past medication compliance or unwillingness to complete the trial.\n* Any other medical conditions that may place the patient at a higher risk due to participation in this study.","6 Years",{"count":170,"type":22},44,[25],"This study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children",[174],"Pediatric Hereditary Kidney Diseases",[176,177,178,179],"hereditary kidney diseases","proteinuria","dapagliflozin","children",{"date":130,"type":35},{"date":182,"type":35},"2025-03-22",{"date":184,"type":22},"2027-03-31",{"name":41,"class":42},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":17,"minAge":193,"maxAge":19,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":102},"100554514","effects-of-intermittent-dietary-restriction-on-cardiometabolic-risk-in-school-aged-children-100554514","NCT06500078","Effects of Intermittent Dietary Restriction on Cardiometabolic Risk in School-aged Children","Effects of Intermittent Dietary Restriction on Cardiometabolic Risk in School-aged Children: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 7-18 years at baseline.\n* At least one of the following cardio-metabolic abnormalities:\n\n  1. Prediabetes (Impaired fasting glucose: 5.6 ≤ fasting blood glucose level ≤ 6.9 mmol\u002FL; or Impaired glucose tolerance: 7.8 ≤ blood glucose level after 2 hours postprandial ≤ 11.0 mmol\u002FL).\n  2. Lipid abnormalities (High-density lipoprotein cholesterol ≤ 1.04 mmol\u002FL; or Low-density lipoprotein cholesterol ≥ 3.37 mmol\u002FL; or Triglycerides ≥ 1.70 mmol\u002FL, or Total cholesterol ≥ 5.18 mmol\u002FL).\n  3. Elevated blood pressure (Systolic\u002Fdiastolic blood pressure consistently higher than the 90th percentile for gender, age, and height; or systolic\u002Fdiastolic blood pressure ≥ 120\u002F80 mmHg).\n\nExclusion Criteria:\n\n* Previously diagnosed with heart failure, severe malnutrition, immune deficiency, liver or kidney disease, cancer, or other diseases deemed unsuitable for participation.\n* Had a history of bariatric surgery.\n* Used weight loss pills or supplements in the last three months.\n* Other situations unsuitable for participation.","7 Years",{"count":195,"type":22},324,[86],"This randomized trial aims to evaluate the health-promoting effects of intermittent dietary restrictions, including intermittent low-carbohydrate diet (ILCD) and calorie restriction (ICR), in school-aged children with cardiometabolic risk (CMR) compared with general health education based on dietary and physical activity guidelines for Chinese children.",[199],"Cardiovascular Syndrome, Metabolic",[201,202,203,204],"Intermittent carbohydrate restriction","Intermittent calorie restriction","Cardiometabolic risk","Children",{"date":130,"type":35},{"date":207,"type":35},"2024-07-13",{"date":209,"type":22},"2027-12-31",{"name":41,"class":42},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":102},"100500080","the-intervention-of-obesity-in-children-with-prader-willi-syndrome-using-prebiotics-and-probiotics-100500080","NCT05791604","The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics","The Safety and Effectiveness Study of Prebiotics and Probiotics in the Intervention of Obesity in Children With Prader-Willi Syndrome","Inclusion Criteria:\n\n* Pre-adolescent children with Prader Willi syndrome which were definitely diagnosed by gene testing.\n* Consistent with the diagnostic criteria for obesity.\n* Not participate in other research projects at present or three months before the research;\n* Agree to participate in the test and obtain the consent of their parents; voluntarily be the subjects and sign the informed consent form.\n\nExclusion Criteria:\n\n* Losing weight in ways other than the intervention measures of this project, such as taking weight loss drugs or known drugs that cause weight change;\n* Use antibiotics within 1 month before the study and lasted for 3 days or more;\n* Use probiotics within 1 month before the study and lasted for 3 days or more;\n* Complicated with liver and renal insufficiency (alanine aminotransferase and serum creatinine indexes exceed 2 times the upper limit of the normal value set by the hospital);\n* Have gastrointestinal diseases affecting food digestion and absorption (such as severe diarrhea, constipation, severe gastrointestinal inflammation, active gastrointestinal ulcer, acute cholecystitis, etc.); severe diarrhea refers to watery stool 3 or more times a day and lasts for 3 or more days. severe constipation refers to defecation 2 or less times a week with difficulty in defecation;\n* Surgery was performed within 1 year before the study (except for appendicitis and hernia surgery);\n* Have hepatitis B, active tuberculosis, AIDS and other infectious diseases;\n* Those who are suffering from mental illness and are taking psychotropic drugs such as antidepressants.","3 Years","10 Years",{"count":84,"type":22},[86],"Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. More and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children.",[224],"Prader-Willi Syndrome",[226,227,228],"Prader-Willi syndrome","Probiotics","Prebiotics",{"date":130,"type":35},{"date":231,"type":35},"2023-04-01",{"date":233,"type":22},"2029-07-31",{"name":41,"class":42},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":243,"maxAge":19,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":102},"100488710","phase-4-rivaroxaban-for-children-aged-over-2-years-with-giant-coronary-artery-aneurysms-after-kawasaki-disease-100488710","NCT05643651","Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease: a Multicenter, Open-label, Parallel, Exploratory, Randomized Controlled Trial","RIVA-KG","Inclusion Criteria:\n\n1. Giant coronary artery aneurysm(s) in any coronary artery after acute stage of Kawasaki disease. Giant coronary artery aneurysm(s) should be confirmed by two-dimensional echocardiography and meet the diagnostic criteria of Z-score ≥10 or coronary artery internal diameter ≥8mm;\n2. Anticoagulant with antiplatelet drug therapy for anti-thromboprophylaxis is recommended for the next 3 months;\n3. Participant should be able to tolerate oral feeding, nasogastric or gastric feeding;\n4. Children aged ≥ 2 years\n\nExclusion Criteria:\n\n1. Active bleeding or bleeding risk contraindicating anticoagulant therapy\n2. With history of venous thromboembolism or risk factors related with venous thromboembolism, like congenital heart disease, carcinoma, central venous catheter or long-term immobilization.\n3. Thrombus within giant coronary aneurysm was confirmed by previous imaging examinations, including two-dimensional echocardiography, computed tomography angiography in coronary artery or coronary angiography\n4. An eGFR \\\u003C30mL\u002Fmin\u002F1.73 m2 (For children younger than 1 year, serum creatinine results above 97.5th percentile)\n5. Platelet count \\\u003C 100 x 109\u002FL\n6. Hepatic disease which is associated with either: coagulopathy leading to a clinically relevant bleeding risk, or alanine aminotransferase \\> 5x ULN or total bilirubin \\> 2x ULN with direct bilirubin \\> 20% of the total\n7. Sustained uncontrolled hypertension defined as systolic and\u002For diastolic blood pressure \\>95 th age percentile\n8. Concomitant use of strong inhibitors of both CYP3A4 and P-glycoprotein, including but not limited to all human immunodeficiency virus protease inhibitors and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically (fluconazole is allowed)\n9. Concomitant use of strong inducers of CYP3A4, including but not limited to rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine\n10. Hypersensitivity or any other contraindications listed in the local labeling for the comparator treatment or experimental treatment\n11. Inability to cooperate with the study procedures and follow-up visits\n12. Refuse to provide informed consent eGFR, estimated glomerular filtration rate; ULN, upper level of normal; TB, total bilirubin; CYP3A4, cytochrome P450 isoenzyme 3A4","2 Years",{"count":245,"type":22},100,[247],"PHASE4","Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed. This exploratory trial aims to evaluate the feasibility, safety and effectiveness of rivaroxaban compared to warfarin for thromboprophylaxis in children aged over 2 years with giant coronary artery aneurysms after Kawasaki disease",[59,250],"Coronary Artery Aneurysm",[252,253,254,255,256],"Kawasaki disease","Giant coronary artery aneurysm","Rivaroxaban","Warfarin","Anticoagulation",{"date":130,"type":35},{"date":98,"type":35},{"date":260,"type":22},"2027-09-01",{"name":41,"class":42},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":17,"minAge":243,"maxAge":19,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":102},"100633742","phase-3-statins-study-in-children-of-acute-kawasaki-disease-with-coronary-artery-abnormalities-100633742","NCT07530640","Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities","Clinical Study of Atorvastatin in the Treatment of Acute Kawasaki Disease Complicated With Coronary Artery Abnormalities in Children","Inclusion Criteria:\n\n* KD complicated with CAA, less than 20 days after the onset of KD, or more than 20 days after onset but the KD inflammation has not been controled.\n* IVIG and\u002For other anti-inflammatory treatments have been used\u002Fare being used.\n* The guardians agree to atorvastatin treatment and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with history of family hypercholesterolemia\u002Ftaking statins\u002Fsevere chronic diseases.\n* Patients with abnormal laboratory data including CK≥500U\u002FL, total cholesterol\\\u003C3.1mmol\u002FL, ALT or AST≥ 2 times the upper limit of normal.\n* The guardians do not agree to atorvastatin treatment.",{"count":43,"type":22},[25],"The goal of this observational study is to learn about the safety and effects of atorvastatin in treatment of Chinese Kawasaki disease (KD) children complicated with coronary artery abnormalities (CAA) in acute phase. The main questions it aims to answer are: Is atorvastatin safe in Chinese children of acute KD? Does atorvastatin contribute to control the acute inflammation in KD and improve the CAA?",[59,273],"Coronary Artery Abnormalities",[59,275,276,277],"Coronary artery abnormalities","Atorvastatin","Acute","2026-06-14",{"date":280,"type":35},"2026-06-16",{"date":282,"type":35},"2026-06-08",{"date":284,"type":22},"2027-09-30",{"name":41,"class":42},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":294,"minAge":295,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":314},"100643082","clinical-study-of-traditional-chinese-medicine-in-the-treatment-of-phlegm-dampness-intrinsic-precocious-puberty-100643082","NCT07637019","Clinical Study of Traditional Chinese Medicine in the Treatment of Phlegm-dampness Intrinsic Precocious Puberty","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Sanghe Jianghuo Granules in the Treatment of Girls Aged 5-8.5 Years With Precocious Puberty and Phlegm-Dampness Internal Accumulation Syndrome According to Traditional Chinese Medicine","SHJG-PP","Inclusion Criteria:\n\n1. Female, aged between 5 and 9 years (inclusive).\n2. Presence of secondary sexual characteristics before 8 years of age, consistent with simple premature thelarche \u002F initial central precocious puberty (CPP) \u002F Tanner stage II.\n3. Traditional Chinese Medicine (TCM) syndrome differentiation: Phlegm-dampness internal accumulation syndrome.\n4. Body mass index (BMI) greater than the 50th percentile for same age and sex.\n5. Initial case, no prior medication for precocious puberty (including but not limited to GnRHa, sex hormones, growth hormones, Zhibai Dihuang Wan, Dabuyin Wan, or traditional Chinese weight-loss medicines) within the last 3 months.\n6. Informed consent signed by the legal guardian(s), with ability to comply with the follow-up schedule.\n\nExclusion Criteria:\n\n1. Secondary precocious puberty due to central nervous system organic lesions, thyroid or adrenal disorders, ovarian tumors, or other underlying conditions.\n2. Severe hepatic or renal dysfunction, or hematological diseases.\n3. Use of sex hormones, growth hormones, Zhibai Dihuang Wan, Dabuyin Wan, or traditional Chinese weight-loss medicines within the last 3 months.\n4. Inability to cooperate with examinations or poor compliance with follow-up visits (e.g., inability to complete ultrasound, blood collection, or scheduled visits).","FEMALE","5 Years","9 Years",{"count":112,"type":22},[86],"Precocious puberty is characterized by the premature appearance of secondary sexual characteristics. Globally, the timing of puberty onset in children has shown a certain tendency to advance. In China, the incidence of precocious puberty has been increasing year by year. Precocious puberty exerts long-term and systemic impacts on children's health: advanced bone age leads to short stature; earlier sexual development than peers may induce emotional problems such as anxiety and inferiority; it may increase the risk of obesity and type 2 diabetes, posing long-term hazards to cardiovascular health; it may also result in irregular menstruation or dysmenorrhea, exerting indirect effects on reproductive health.\n\nModern traditional Chinese medicine (TCM) holds that: various factors lead to liver-kidney yin deficiency, hyperactivity of ministerial fire, and early arrival of tian gui (the substance responsible for promoting growth, development and reproduction), thereby triggering premature sexual development. The main syndrome types identified in clinical practice include yin deficiency with fire hyperactivity syndrome, liver stagnation transforming into fire syndrome, and phlegm-dampness internal accumulation syndrome.\n\nSince the late 1970s, the investigators' department has taken the lead in treating precocious puberty with TCM diagnostic methods, proposing that the pathogenesis of precocious puberty lies in \"kidney yin deficiency and hyperactivity of ministerial fire\", and adopting the therapy of nourishing yin and purging fire for its treatment. A number of studies have confirmed that TCM medicines with the effects of nourishing yin and purging fire can effectively alleviate the yin deficiency with fire hyperactivity syndrome in children, delay the development of secondary sexual characteristics and bone age.\n\nAt present, central precocious puberty is mostly treated with gonadotropin-releasing hormone analogs (GnRHa). However, this treatment has the drawback of inhibiting the growth axis, yielding limited benefits for children with advanced bone age, overweight or obesity, and may even affect glucose and lipid metabolism. Moreover, some children with precocious puberty complicated with obesity may be intolerant to this therapy. In contrast, TCM therapy and integrated TCM-Western medicine therapy can effectively delay the development of secondary sexual characteristics and advanced bone age, and improve final adult height, thus being widely applied in China.\n\nAlthough a large number of relevant studies have been reported in recent years and TCM diagnosis and treatment guidelines for precocious puberty have been formulated, there is still a lack of high-quality evidence-based medical research to support the advantageous aspects of integrated TCM-Western medicine diagnosis and treatment. Additionally, the underlying mechanisms of diagnosis and treatment for different syndrome types of precocious puberty remain insufficiently studied.\n\nIn this study, the investigators will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of Sanghe Jianghuo Granules on the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, metabolic homeostasis and inflammatory microenvironment, so as to verify its efficacy and safety. Furthermore, combined with transcriptomics, proteomics and network pharmacology, the investigators will identify the key targets and action pathways of Sanghe Jianghuo Granules, and verify its regulatory effect on the HPG axis through in vivo and in vitro experiments.",[301],"Precocious Puberty",[301,303,304,305],"Sanghe Jianghuo Granules","Traditional Chinese Medicine","Phlegm-Dampness Syndrome","2026-06-04",{"date":308,"type":35},"2026-06-09",{"date":310,"type":22},"2026-07-01",{"date":312,"type":22},"2028-06-30",{"name":41,"class":42},5,{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":322,"targetDuration":18,"studyType":324,"phases":4,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":336},"100403182","child-parent-familial-hypercholesterolemia-screening-100403182","NCT04529967","Child-Parent Familial Hypercholesterolemia Screening","Child-Parent Screening of Familial Hypercholesterolemia in Children","Inclusion Criteria:\n\n* Receive routine child care\n* aged 1 - 3 years old ( date of investigate minus date of birth)\n\nExclusion Criteria:\n\n* It is up to the researcher to decide whether it is suitable to participate in this research",{"count":323,"type":22},15000,"OBSERVATIONAL","Child-parent screening for familial hypercholesterolemia has been proposed to identify children and their parent who are carrier of mutations and with high risk for inherited premature coronary artery disease. The investigators assessed the efficacy and feasibility of such screening in primary care practice.\n\nkey scientific questions:\n\n1. The 95th and 99th percentile of finger blood TC in children of 2 years old.\n2. Mutations that contribute to high TC status ( serum TC \\>99th percentiles) compared with international FH48 panel for FH genetic screening.",[327],"Familial Hypercholesterolemia","2026-05-13",{"date":330,"type":35},"2026-05-15",{"date":332,"type":35},"2025-04-01",{"date":334,"type":22},"2026-09-30",{"name":41,"class":42},6,{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":168,"maxAge":19,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":4},"100640538","feasibility-and-preliminary-efficacy-of-a-child-life-based-breathing-exercise-program-for-children-recovering-from-severe-pneumonia-a-pilot-randomized-controlled-trial-100640538","NCT07593989","Feasibility and Preliminary Efficacy of a Child Life-Based Breathing Exercise Program for Children Recovering From Severe Pneumonia: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Children aged 6-18 years.\n2. Diagnosed with severe pneumonia and in the recovery phase.\n3. Written informed consent is obtained from caregivers, and assent is obtained from children when appropriate.\n\nExclusion Criteria:\n\n1. Contraindications to breathing exercise, including: (a) hemodynamic instability (e.g., bradycardia or tachycardia, arrhythmia, hypotension or hypertension); (b) open sternal incision; (c) extracorporeal membrane oxygenation (ECMO); (d) acute phase of severe wheezing or stridor; and (e) severe pulmonary hypertension.\n2. Communication disorders.",{"count":344,"type":22},30,[86],"The goal of this pilot randomized controlled trial is to evaluate the feasibility and preliminary efficacy of a child life-based breathing exercise program for children recovering from severe pneumonia. The main questions it aims to answer are:\n\n* Is the child life-based breathing exercise program feasible for hospitalized children recovering from severe pneumonia?\n* Can the program improve caregiver satisfaction and promote recovery in children with severe pneumonia?\n\nResearchers will compare a child life-based breathing exercise program combined with routine health education with routine health education alone to determine whether the intervention improves rehabilitation outcomes.\n\nParticipants will:\n\n* Receive either routine health education alone or routine health education combined with the child life-based breathing exercise program\n* Participate in breathing exercise training during hospitalization\n* Complete assessments of caregiver satisfaction and clinical recovery outcomes, including improvement in chest imaging findings and time to resolution of symptoms such as cough, fever, and dyspnea.",[348],"Severe Pneumonia","2026-05-12",{"date":351,"type":35},"2026-05-18",{"date":353,"type":22},"2026-06-01",{"date":355,"type":22},"2027-06-01",{"name":41,"class":42},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":17,"minAge":365,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":374,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":102},"100601793","effectiveness-of-high-energy-density-enteral-nutrition-for-enhancing-physical-growth-and-cognitive-brain-development-in-infants-with-congenital-heart-disease-100601793","NCT07115108","Effectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease","Effectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease: A Randomized Controlled Study","RCT","Inclusion Criteria:\n\n* Diagnosed with congenital heart disease through symptoms, physical signs, imaging, and ultrasound examinations.\n* Age 0-6 months\n* Children with nutritional risks (defined by STRONGkids: Nutritional risk screening tool for children )\n* Artificial or mixed feeding\n* Open heart surgery under cardiopulmonary bypass\n* The guardians of the children voluntarily participate in this study and sign a written informed consent form before the surgery.\n\nExclusion Criteria:\n\n* Diagnosed with major non cardiac diseases leading to nutritional intake disorders, such as congenital gastrointestinal malformations, preoperative diagnosis of gastroesophageal reflux, genetic diseases related to growth restriction, and various syndromes with chromosomal abnormalities (trisomy 21 syndrome, trisomy 18 syndrome)\n* Abnormal immune system function due to congenital or acquired factors, unable to effectively resist pathogens or eliminate abnormal cells, which can be divided into primary and secondary immunodeficiencies.\n* Any pre - operative history of neurological diseases (e.g., encephalitis, epilepsy).\n* Secondary or primary gastrointestinal infection symptoms such as abdominal distension and diarrhea after surgery.\n* Estimated stay time in the postoperative intensive care unit ≤ 2 days","0 Months","6 Months",{"count":368,"type":22},160,[86],"The purpose of this study is to compare the effect of high and ordinary energy density enteral nutrition for improving physical growth and brain cognitive development in infants with congenital heart disease after operation, as well as evaluate the safety of interventions.",[372,373,148],"Congenital Heart Disease","Enteral Nutrition",[375,376,148],"Congenital heart disease","Enteral nutrition",{"date":328,"type":35},{"date":379,"type":35},"2025-10-13",{"date":381,"type":22},"2026-12-31",{"name":41,"class":42},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":390,"maxAge":19,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":399,"leadSponsor":401,"locationsCount":102},"100592967","early-phase-1-cs-206-in-patients-with-sickle-cell-disease-100592967","NCT07000318","CS-206 in Patients With Sickle Cell Disease","An Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CD34+ Human Hematopoietic Stem Cells Modified Using Transformer Base Editor in Participants With Severe Sickle Cell Disease","Inclusion Criteria:\n\n* Participants must be between 12 to 18 years old (inclusive). Participants or their legal guardians (for participants below 18 years old) must provide written informed consent before any study-related procedures.\n* Participants must have a Documented βS\u002FβS, βS\u002Fβ0 or βS\u002Fβ+ genotype.\n* Participants must have at least one of the following conditions\n\n  1. At least 2 occurrences of any of the following events within 2 years prior to screening.\n\n     1. Acute pain crisis: requiring a visit to a medical facility and administration of pain medications (opioids or intravenous NSAIDs) or red blood cell transfusions.\n     2. Acute chest syndrome: defined by the presence of a new pulmonary infiltrate on a chest X-ray, associated with pneumonia-like symptoms, including chest pain, fever, or respiratory distress.\n     3. Priapism lasting more than 2 hours and necessitating a visit to a medical facility for intervention.\n     4. Stroke or transient ischemic attack (TIA): confirmed by imaging studies (e.g., MRI or CT scan), including silent stroke, and overt stroke leading to neurological deficits lasting \\>24 hours.\n  2. Presence of red cell alloimmunization (\\>2 antibodies) and the need for ongoing chronic transfusions.\n  3. Participants who have failed, not tolerated, refused the standard of care for Sickle Cell Disease (SCD), or are unable to access the standard of care due to the availability\n  4. Other situations deemed appropriate for hematopoietic stem cell transplantation according to the sickle cell anemia treatment guidelines, as determined by the investigator.\n* Laboratory Parameters:\n\n  1. Documented Hemoglobin S (HbS) level ≥30% of total hemoglobin (Hb) concentration prior to transfusion.\n  2. HbF at screening \\\u003C 20%\n* Participants must have a Karnofsky Performance Status (KPS for participants above 16 years old, inclusive) or Lansky Play-Performance Scale (LPPS for participants below 16 years old) score of ≥70, indicating sufficient functional status to undergo the intervention.\n* Willing to comply with the protocol requirements, use contraception as required, attend regular follow-up visits, and cooperate with examinations\n\nExclusion Criteria:\n\n* Female participants who are pregnant, breastfeeding, or planning pregnancy during the study period are excluded.\n* Participation in another investigational drug trial within 30 days prior to screening or within 5 half-lives (whichever is longer).\n* Subjects who have received or are receiving luspatercept treatment within 3 months prior to screening.\n* Subjects who have previously received any gene therapy for the disease.\n* Subjects with a fully matched related donor who are already scheduled for allogeneic hematopoietic stem cell transplantation.\n* More than 10 unplanned hospitalizations or emergency visits within 12 months prior to screening, which the investigator believes are related to significant chronic pain rather than acute pain crisis (VOC).\n* Severe liver dysfunction:\n\n  1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3× the upper limit of normal (ULN) or:\n  2. International Normalized Ratio (INR) \\>1.5× ULN\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin\u002F1.73 m²) are excluded.\n* Subjects with HIV, cytomegalovirus (CMV), Epstein-Barr virus (EBV), or Treponema pallidum infection during the screening period; those with active HBV or HCV infection; or known tuberculosis or parasitic infection, etc. Excludes subjects with stable hepatitis B (HBV-DNA negative) after treatment and those cured of hepatitis C (HCV-RNA negative). Known active bacterial, viral, or fungal infections.\n* Deemed unsuitable for autologous hematopoietic stem cell transplantation procedures as determined by the investigator.\n* Other situations deemed unsuitable for this study as determined by the investigator.","12 Years",{"count":314,"type":22},[393],"EARLY_PHASE1","The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-206 injection in treating sickle cell disease.",[396],"Sickle Cell Disease",{"date":330,"type":35},{"date":334,"type":22},{"date":400,"type":22},"2029-03-31",{"name":41,"class":42},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":23,"phases":410,"briefSummary":411,"conditions":412,"keywords":415,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":420,"locationsCount":102},"100580043","close-loop-smart-weaning-for-ino-with-pphn-100580043","NCT06832163","Close Loop Smart Weaning for INO With PPHN","Close Loop Smart Weaning Protocol for Inhaled Nitric Oxide Therapy With PPHN","Inclusion Criteria:\n\n1. The administration of inhaled nitric oxide (iNO) has commenced or is anticipated to commence for a duration of 24 hours or more, based on a clinical diagnosis of persistent pulmonary hypertension of the newborn (PPHN);\n2. There is a demonstrable positive response to iNO treatment;\n3. The iNO delivery system employed is appropriate and meets the conditional requirements, featuring an intelligent closed-loop offline functionality;\n4. The guardian or legal representative possesses a comprehensive understanding of the potential benefits and risks associated with participation in this study and has expressed a willingness to consent by signing the informed consent document.\n\nExclusion Criteria:\n\n1. There are established contraindications associated with the use of nitric oxide, which include the following conditions:\n\n   1. Severe hypoplasia of the left heart or duct-dependent congenital heart disease;\n   2. Life-threatening congenital anomalies and congestive heart failure;\n   3. Congenital methemoglobinemia;\n   4. Significant hemorrhagic events, such as intracranial hemorrhage, intraventricular hemorrhage, and pulmonary hemorrhage.\n2. Patients with chronic pulmonary conditions and other refractory diseases are not permitted to initiate withdrawal from the inhaled nitric oxide (iNO) treatment within a seven-day period following its administration.\n3. In cases where there is no observable response to iNO or if the duration of use is less than 30 minutes, a strict tapering protocol for withdrawal is not required.\n4. If the concentration of iNO treatment exceeds 20 parts per million (ppm) during the initiation phase or if the starting concentration for withdrawal is below 20 ppm, specific considerations must be taken into account.\n5. Participation in concurrent clinical trials involving other pharmacological agents or medical devices is prohibited.\n6. The investigator may determine that participation in this study is not appropriate for certain individuals.",{"count":344,"type":22},[86],"In contemporary clinical practice concerning the administration of inhaled nitric oxide (iNO) within neonatal intensive care units (NICUs), a stepwise reduction approach is frequently employed in accordance with established neonatal guidelines. Nonetheless, the comparative advantages of a linear reduction strategy-characterized by a gradual decrease in inhalation concentration-over the traditional stepwise method in terms of efficacy and safety have yet to be conclusively established. Furthermore, existing iNO delivery devices necessitate that healthcare professionals manually adjust parameters at intervals dictated by the patient's condition. This reliance on subjective clinical judgment often results in variability and a lack of standardization in the duration of the weaning process. Additionally, the protracted and intricate nature of the weaning procedure considerably heightens the workload for healthcare staff. Importantly, the development of a scientifically grounded, standardized, and real-time feedback mechanism for weaning may enhance clinical outcomes for patients and mitigate the risks associated with inappropriate weaning practices or inconsistent manual interventions. Consequently, this study seeks to leverage the newly introduced \"intelligent closed-loop weaning\" feature of the latest generation of iNO devices to facilitate automated linear concentration reduction during the weaning process. This innovation aims to alleviate the burden on healthcare personnel while establishing a more standardized and scientifically robust weaning protocol. However, it is noteworthy that there is currently a lack of clinical evidence, both domestically and internationally, regarding the safety and efficacy of this device's weaning protocol, underscoring the urgent need to validate its safety and effectiveness in real-world clinical settings.",[413,414],"Persistent Pulmonary Hypertension of the Newborn","Inhaled Nitric Oxide",[414,413],{"date":328,"type":35},{"date":418,"type":35},"2025-10-01",{"date":381,"type":22},{"name":41,"class":42},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":428,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":102},"100510351","preventive-effect-of-prophylactic-oral-antibiotics-against-cholangitis-after-kasai-portoenterostomy-100510351","NCT05925309","Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients whose age of operation is 14-90 d. Sex and race are not restricted;\n* Patients who are born with gestational age older than 36 weeks;\n* Patients whose body weight before operation \\> 2 kg;\n* Patients diagnosed of type-III BA and underwent KP in Children's Hospital of Fudan University;\n* The type-III BA diagnosis is based on cholangiography or operation;\n* Patients whose histological features of liver biopsies are reported. HE staining and Masson staining are required, and edema, inflammation, fibrosis, and hyperplasia of intrahepatic bile duct should be reported;\n* Patients who are not allergic to postoperative medications;\n* Patients who haven't accepted other antibiotic or probiotic therapy.\n\nExclusion Criteria:\n\n* Patients with cholestasis of non-BA disease;\n* Patients who have undergone KP at other institutions;\n* Patients whose pathohistological diagnosis is in doubt;\n* Patients who undergo liver transplantation immediately after KP;\n* Patients with other liver diseases or severe complications (e.g., severe pulmonary hypertension, renal failure, intracranial hemorrhage, etc.) requiring surgical intervention or other medical therapy;\n* Patients with severe cardiac, renal, or central nerve system malformations (e.g., tetralogy of Fallot, transposition of the great arteries, cerebral dysplasia, etc.) and have poor prognosis;\n* Patients judged by the researchers that they can not comply with the study requirements.","14 Days","90 Days",{"count":431,"type":22},356,[86],"This study is non-inferiority trial design. This study aimed to investigate the effect of prophylactic oral antibiotics on preventing cholangitis in biliary atresia (BA) patients after Kasai portoenterostomy (KP) by comparing the cholangitis rate in BA patients who received prophylactic oral antibiotics and those who did not. The patients were followed up for 2 years after KP.",[435,436,437],"Biliary Atresia","Cholangitis","Anti-Bacterial Agents",{"date":330,"type":35},{"date":440,"type":35},"2023-07-01",{"date":134,"type":22},{"name":41,"class":42},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":450,"minAge":451,"maxAge":19,"enrollmentInfo":452,"targetDuration":4,"studyType":23,"phases":453,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":102},"100635647","phase-4-evaluating-the-safety-and-efficacy-of-decitabine-in-the-treatment-of-xmen-patients-100635647","NCT07555405","Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients","Single-arm Clinical Study Evaluating the Safety and Efficacy of Decitabine in the Treatment of X-linked MAGT1 Deficiency With Increased Susceptibility to EBV Infection and N-linked Glycosylation Defect (XMEN) Patients","Inclusion Criteria:\n\n1. Male participants aged 1 month to 18 years old.\n2. Confirmed MAGT1 gene mutation by genetic testing.\n3. Clinical manifestations consistent with XMEN disease, including liver dysfunction and\u002For EBV infection.\n4. Reduced lymphocyte NKG2D expression.\n5. Vital signs within normal range at screening.\n6. Expected survival ≥ 6 months.\n7. Able to comply with study procedures.\n8. Guardian and participant provide written informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity to decitabine or any excipient.\n2. Hematopoietic stem cell transplantation within 1 year before enrollment.\n3. Severe concurrent organ dysfunction or systemic disease.\n4. Positive HBsAg, anti-HCV, syphilis, or HIV test.\n5. Neurological or psychiatric disorders that impair compliance.\n6. Participation in another clinical trial within 3 months.\n7. Other conditions judged inappropriate by the investigator.","MALE","1 Month",{"count":336,"type":22},[247],"This is a single-arm, open-label, single-center, exploratory clinical trial evaluating the safety and efficacy of decitabine in male patients aged 1 month to 18 years with X-linked magnesium transporter 1 (MAGT1) deficiency. Eligible patients have a confirmed MAGT1 gene mutation leading to XMEN disease ( X-linked MAGT1 deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect). The study will assess changes in liver function, immune function, and NKG2D expression, as well as adverse events, over four treatment cycles and the follow-up period.",[456],"MAGT1 Deficiency",[458],"Decitabine","2026-04-24",{"date":461,"type":35},"2026-04-29",{"date":463,"type":22},"2026-04",{"date":465,"type":22},"2028-12",{"name":41,"class":42},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":474,"enrollmentInfo":475,"targetDuration":4,"studyType":324,"phases":4,"briefSummary":477,"conditions":478,"keywords":482,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":491,"locationsCount":102},"100444837","high-medium-chain-triglyceride-nutritional-support-in-infants-with-biliary-atresia-100444837","NCT05072626","High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia","Study on High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia After Kasai Portoenterostomy","Inclusion Criteria:\n\nThe Kasai procedure for infants with biliary atresia under the age of 3 months.\n\nExclusion Criteria:\n\n* Complicated with cirrhosis, hepatitis, or other hepatic disorders;\n* Complicated with other systemic serious diseases (such as congenital multiple malformations, chromosome abnormalities)","3 Months",{"count":476,"type":22},300,"This study is a prospective, single center and observational open clinical study.",[435,479,480,481],"Infant","Nutrition Support","Medium-chain Triglyceride",[435,483,480,484],"Kasai portoenterostomy","medium-chain triglyceride","2026-03-30",{"date":487,"type":35},"2026-04-03",{"date":489,"type":35},"2021-10-11",{"date":39,"type":22},{"name":41,"class":42},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":366,"enrollmentInfo":499,"targetDuration":4,"studyType":324,"phases":4,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":102},"100416804","enteral-nutrition-in-infants-with-ileostomy-100416804","NCT04707443","Enteral Nutrition in Infants With Ileostomy","Correlation Between Enteral Nutrition and Early Prognosis in Infants Aged Under 6 Months Following Enterostomy","Inclusion Criteria:\n\n* After birth, infants aged 0-6 months (including neonates) undergo small bowel ostomy for various reasons.\n\nExclusion Criteria:\n\n* Primary liver and kidney dysfunction, congenital multiple malformations and chromosomal abnormalities.",{"count":500,"type":22},110,"This study is a prospective, single center, practical, and observational open clinical study.",[503],"Nutrition of Ileostomy Infants",[505,506,376,507,508],"ileostomy","Human breast milk","extensive hydrolyzed formula","amino acid formula",{"date":487,"type":35},{"date":511,"type":35},"2021-07-08",{"date":39,"type":22},{"name":41,"class":42},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":451,"maxAge":19,"enrollmentInfo":521,"targetDuration":218,"studyType":324,"phases":4,"briefSummary":523,"conditions":524,"keywords":533,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":102},"100567463","magnetoencephalography-in-children-100567463","NCT06668519","Magnetoencephalography in Children","An Observational Study on the Clinical Application of Magnetoencephalography in Children With Neurodevelopmental Disorders","Inclusion Criteria:\n\n1. aged 1 month-18 years old (date of investigate minus date of birth)\n2. epilepsy\n3. intracranial tumors\n4. cerebrovascular diseases\n5. autism\n6. mental retardation\n7. ADHD\n8. tic disorder\n9. neuropsychiatric disorders\n\nExclusion Criteria:\n\n1.Unable to cooperate with the exam of MEG",{"count":522,"type":22},1500,"This study is a single-center observational clinical study, which evaluates the diagnostic value of magnetoencephalography (MEG) in the diagnosis of neurodevelopmental diseases in children, such as the localization of epileptic foci and brain functional areas, intracranial tumors, cerebrovascular diseases, autism, mental retardation, and neuropsychiatric disorders.",[525,526,527,89,528,529,530,531,532],"Epilepsy","Intracranial Tumors","Cerebrovascular Disease","ADHD - Attention Deficit Disorder With Hyperactivity","Neuropsychiatric Disorders","Tic Disorder, Childhood","Mental Retardation","Developmental Disabilities",[534,535,536],"neurodevelopmental diseases","magnetoencephalography","pediatric","2026-03-24",{"date":539,"type":35},"2026-03-25",{"date":541,"type":35},"2024-09-25",{"date":543,"type":22},"2027-12-30",{"name":41,"class":42},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":551,"sex":17,"minAge":4,"maxAge":168,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":554,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":72},"100517537","urine-and-ultrasound-screening-for-kidney-disease-in-children-100517537","NCT06018831","Urine and Ultrasound Screening for Kidney Disease in Children","Inclusion Criteria:\n\n* All consecutive live newborn infants(regardless of physical condition)\n* Complete at least 3 years of follow-up\n\nExclusion Criteria:\n\n* Declining the screening\n* Missing",true,{"count":553,"type":22},13000,[86],"The aim of this study is to early detect kidney disease in the natural population cohort of children by urine and ultrasound screening, to assist in the precise prevention and treatment of children's kidney disease, and to establish a risk prediction system for children's kidney disease. About 10,000 children called KunQi Cohort are born in Jiangsu Province(8,000 in Kunshan and 2,000 in Qidong) and about 3,000 born in Shanghai. Through the project, child who is found with abnormal urine or ultrasound result will be referred to Children's Hospital of Fudan University to get further examination and treatment.",[557,558,559,560,561],"Kidney Diseases","Diagnostic Techniques","Ultrasound","Urinalysis","Child, Only",{"date":563,"type":35},"2026-03-27",{"date":565,"type":35},"2022-04-12",{"date":567,"type":22},"2028-02",{"name":41,"class":42},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":324,"phases":4,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":102},"100504438","preoperative-serum-fgf19-in-the-prognosis-of-biliary-atresia-100504438","NCT05848310","Preoperative Serum FGF19 in the Prognosis of Biliary Atresia","Inclusion Criteria:\n\n* Samples diagnosed as biliary atresia in Children's Hospital of Fudan University\n* Samples with one-year follow-up records after surgery\n* Samples with a record of serum total bilirubin levels three months after surgery\n* Samples with preoperative serum left（volume \\> 500ul)\n\nExclusion Criteria:\n\n* None",{"count":112,"type":22},"To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.",[435,578],"Prognosis",[435,580],"FGF19",{"date":563,"type":35},{"date":583,"type":35},"2023-10-15",{"date":585,"type":22},"2027-08",{"name":41,"class":42},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":168,"enrollmentInfo":594,"targetDuration":4,"studyType":23,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":102},"100403054","whole-genome-sequencing-versus-whole-exome-sequencing-for-congenital-diarrhea-and-enteropahty-100403054","NCT04528303","Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty","A Randomized, Controlled Trial of the Effectiveness of Whole Genome Sequencing Versus Whole Exome Sequencing for Screening Patients With Congenital Diarrhea and Enteropathy (CODESeq)","Inclusion Criteria:\n\n* Patients with chronic diarrhea lasting greater than 2 months\n* Patients with consent from parents or legal guardians\n* Biological relative of a patient enrolled in this study.\n\nExclusion Criteria:\n\n* Chronic diarrhea caused by specific infections, i.e. CMV, Clostridioides difficile\n* Chronic diarrhea with necrotizing enterocolitis, short bowel syndrome\n* Functional diarrhea\n* Patients with previously confirmed monogenic diarrhea\n* Patients with poor compliance",{"count":595,"type":22},180,[86],"This study will seek to determine if whole genome sequencing (WGS) improves diagnostic rates, and outcomes for congenital diarrhea and enteropathy (CODE) patients. The investigator will enroll 180 patients in a randomized controlled study to either WGS or whole exome sequencing (WES). This study is designed to evaluate whether CODE patients would benefit from WGS guided precision medicine.",[599,600],"Diarrhea, Infantile","Enteropathy","2026-03-20",{"date":537,"type":35},{"date":604,"type":35},"2024-05-01",{"date":381,"type":22},{"name":41,"class":42},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":168,"maxAge":19,"enrollmentInfo":614,"targetDuration":4,"studyType":23,"phases":616,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":630,"locationsCount":102},"100504374","effects-of-auricular-acupressure-versus-intermittent-dietary-restriction-in-children-with-gastric-heat-and-dampness-obstruction-100504374","NCT05847478","Effects of Auricular Acupressure Versus Intermittent Dietary Restriction in Children With Gastric Heat and Dampness Obstruction","Effects of Auricular Acupressure Versus Intermittent Dietary Restriction in Children With Gastric Heat and Dampness Obstruction: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Have at least one of the following cardiometabolic risk factors: overweight or obesity, prediabetes, dyslipidemia or elevated blood pressure.\n* Traditional Chinese medical syndrome type is gastric heat and dampness obstruction syndrome.\n\nExclusion Criteria:\n\n* Diagnosis of obesity associated with genetic or endocrine diseases, including hypercortisolism, polycystic ovary syndrome, primary hypothyroidism and hypothalamic obesity.\n* Participating in other clinical trials or have participated in other clinical trials in recent 3 months.\n* Diagnosis of organic diseases, including heart, liver, kidney and brain or infectious diseases and mental diseases.",{"count":615,"type":22},240,[86],"This is a three-month randomized controlled trial to investigate the effects of auricular acupressure versus Intermittent carbohydrate restriction on cardiometabolic risk in obese children with gastric heat and dampness obstruction.",[619],"Obesity, Childhood",[621,622,623],"Auricular acupressure","Intermittent dietary restriction","Gastric Heat and Dampness Obstruction","2026-03-17",{"date":626,"type":35},"2026-03-19",{"date":628,"type":35},"2023-06-07",{"date":381,"type":22},{"name":41,"class":42},""]